Apollo Life Sciences: ASX Announcements

INVESTORS

ASX Announcements

Annual Report

Background Materials

FAQs

Glossary

Corporate Governance

Investor Contact

APOLLO NEWSLETTER

Webcast 01

Webcast 02


Professor Paul Zimmet AO Head of International Diabetes Institute, Melbourne
"The data that I have seen so far makes this one of the most forward looking and best prospects of an oral insulin"
Click here to see Paul Zimmet's view on Apollo's oral insulin


Bill Moss AM Non-Executive Director and Investor
"Apollo has a number of opportunities to grow into the future. Opportunities perhaps that are much greater than many other companies many times their size"
Click here to hear Bill Moss's view on investing in Apollo

ASX Announcements


	02 May 2008 Restructure Update
	30 Apr 2008 Appendix 4C quarterly
	23 Apr 2008 AOP Deloitte appointment
	15 Apr 2008 Apollo Update: Company’s Restructure
	01 Apr 2008 Company Secretary and Update
	18 Mar 2008 Request for suspension of securities from quotation
	18 Mar 2008 Strategic focus on reducing expenditure and realizing assets
	11 Feb 2008 January 2008 Newsletter
	05 Feb 2008 Growth for Apollo's human proteins
	17 Jan 2008 Apollo's Ellipse Skin Science products start to generate revenue
	20 Dec 2007 Apollo's oral insulin - 2007 R&D update and 2008 roadmap
	07 Dec 2007 November 2007 Newsletter
	20 Nov 2007 AGM 2007 Presentation
	20 Nov 2007 AGM 2007 Report
	19 Nov 2007 Apollo launches into Myer with new skincare range
	14 Nov 2007 Apollo's oral insulin - key studies completed for trial
	31 Oct 2007 Appendix 4C Quarterly Report
	31 Oct 2007 October 2007 Newsletter
	31 Oct 2007 Apollo's oral insulin approach confirmed by US research
	22 Oct 2007 2007 Annual Report
	22 Oct 2007 Notice of AGM
	05 Oct 2007 Shareholder Newsletter September 2007
	05 Oct 2007 Bill Moss AM resigns to focus on establishing charities
	03 Oct 2007 Apollo's national phase patent filings
	31 Aug 2007 August 2007 Newsletter
	20 Aug 2007 Apollo enters supply agreement with Millipore
	06 Aug 2007 Apollo's trial success - needle-free drug delivery
	31 Jul 2007 July 2007 Newsletter
	26 Jul 2007 Patent application for oral drug delivery passes international test
	30 Jun 2007 June 2007 Newsletter
	01 Jun 2007 Apollo advances IP position of Oradel Technology
	31 May 2007 May 2007 Newsletter
	30 Apr 2007 April 2007 Newsletter
	30 Apr 2007 Apollo develops needle-free topical vaccine
	30 Apr 2007 Apollo develops needle-free topical vaccine
	30 Apr 2007 Apollo develops needle-free topical vaccine
	05 Apr 2007 Apollo Capital Raising
	31 Mar 2007 March 2007 Newsletter
	10 Mar 2007 Apollo's national phase patent filings for human proteins
	27 Feb 2007 Apollo $5 millioncapital raising (private placement and SPP)
	27 Feb 2007 Investor Presentation February 2007
	21 Feb 2007 Breakthrough oral delivery for arthritis sufferers
	01 Feb 2007 Successful oral insulin toxicity result
	31 Dec 2006 December 2006 Newsletter
	13 Dec 2006 Apollo oral insulin update
	29 Nov 2006 Apollo raises $10 million
	22 Nov 2006 November 2006 Newsletter
	21 Nov 2006 AGM Presentation
	13 Nov 2006 Apollo's human proteins boost stem cell growth
	10 Nov 2006 Apollo Appoints Japanese Distributor
	31 Oct 2006 TNF blocker tablet for arthritis: Apollo begins tests
	24 Oct 2006 October 2006 Newsletter
	17 Oct 2006 Apollo: needle-free psoriasis treatment outperforms competitors
	25 Sep 2006 Apollo's Diabetes Breakthrough
	03 Jul 2006 Transdermal delivery breakthrough: needle-free biologics
	22 Jun 2006 Apollo initiates efficacy studies on oral delivery of proteins
	26 May 2006 Apollo appoints new director
	22 Mar 2006 Apollo reports positive results in Phase 1b psoriasis trial
	07 Mar 2006 Bill Moss invests $2 million in Apollo Life Sciences and joins board
	23 Jan 2006 Apollo Life Sciences Successfully Completes Data Collection for Phase 1b Psoriasis trial
	09 Dec 2005 Apollo Produces Range of Protein Detection Kits:Enters US$8.5 Billion Global Market
	28 Nov 2005 Apollo enters US$400 million R&D reagents market with unique human proteins
	18 Oct 2005 Apollo Life Sciences: Clinical Trial for Psoriasis Treatment Commences
	27 Sep 2005 Apollo grows with acquisition
	01 Sep 2005 Apollo’s human-expressed Interleukin 2 six times more active than competitor
	09 Aug 2005 Apollo blood vessel forming protein substantially outperforms competitor
	27 Jul 2005 Apollo adds 10 more proteins to its library: Total 60